Keywords
substance-induced psychoses
female
Abstract
Methamphetamine is an amphetamine-derived drug that is frequently abused worldwide and has strong addictive effects.Chronic methamphetamine use leads to changes in dopaminergic receptor density after a while.It acts on dopaminergic systems, particularly in the mesolimbic system and striatum, resulting in sensitization and addiction.This change in the dopaminergic system may explain the psychotic symptoms. However, the mechanism of psychosis caused by methamphetamine and sex-specific features have not been fully elucidated. Studies in recent years have shown that methamphetamine and similar stimulants cause an increase in the incidence of schizophrenia and related disorders. Methamphetamine psychosis has a clinical presentation very similar to schizophrenia. Sometimes it is very difficult to distinguish them from each other. In this case report, we discuss a female case who developed psychotic disorder after a single use of methamphetamine.
References
Jayanthi S, Daiwile AP, Cadet JL. Neurotoxicity of methamphetamine: main effects and mechanisms. Exp Neurol 2021; 344: 113795.
Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 2005; 13(3): 141–154.
Elliott JM, Beveridge TJR. Psychostimulants and monoamine transporters: upsetting the balance. Curr Opin Pharmacol 2005; 5(1): 94-100.
Chiang M, Lombardi D, Du J, et al. Methamphetamine-associated psychosis: clinical presentation, biological basis, and treatment options. Hum Psychopharmacol 2019; 34(5): e2710.
Bramness JG, Rognli EB. Psychosis induced by amphetamines. Curr Opin Psychiatry 2016; 29(4): 236–241.
Lappin JM, Sara GE, Farrell M. Methamphetamine-related psychosis: an opportunity for assertive intervention and prevention. Addiction 2017; 112.(6): 927–928.
Sekine Y, Minabe Y, Ouchi Y, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 2003; 160(9): 16991701.
Wearne TA, Cornish JL. A comparison of methamphetamine-induced psychosis and schizophrenia: a review of positive, negative, and cognitive symptomatology. Front Psychiatry 2018; 9: 491.
Grant KM, Levan TD, Wells SM, et al. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol 2012; 7(1): 113–139.
Drug market trends: cocaine amphetamine-type stimulans. https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html (22 Mart 2022 de ulaşıldı)
Daiwile AP, Jayanthi S, Cadet JL. Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts. Neurosci Biobehav Rev 2022; 137: 104674.
Torres OV. Sex differences in psychostimulant abuse: Implications for estrogen receptors and histone deacetylases. Genes (Basel) 2022; 13(5): 892.
Shelly J, Uhlmann A, Sinclair H, et al. First-rank symptoms in methamphetamine psychosis and schizophrenia. Psychopathology 2017; 49(6): 429–435.
Arunogiri S, Foulds JA, McKetin R, Lubman DI. A systematic review of risk factors for methamphetamine-associated psychosis. Aust N Z J Psychiatry 2018; 52(6): 514–529.
Yang M, Yang C, Liu T, London ED. Methamphetamine-associated psychosis: links to drug use characteristics and similarity to primary psychosis. Int J Psychiatry Clin Pract 2020; 24(1): 31–37.
Greenfield SF, Back SE, Lawson K, Brady KT. Substance abuse in women. Psychiatr Clin North Am 2010; 33(2): 339–355.
Balhara YPS, Kuppili PP, Gupta R. Neurobiology of comorbid substance use disorders and psychiatric disorders: current state of evidence. J Addict Nurs 2017; 28(1): 11–26.
Dankı D, Dilbaz N, Okay T, et al. Madde kullanımına bağlı gelişen psikotik bozuklukta atipik antipsikotik tedavisi: bir gözden geçirme. Bağımlılık Dergisi 2005; 6(3): 136-141.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Dependence